2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): what is new?
Open Access
- 20 November 2024
- journal article
- Published by ECO-Vector LLC in Cardiac Arrhythmias
- Vol. 4 (3) , 5-14
Abstract
The article presents key approaches to the diagnosis and treatment of atrial fibrillation in light of the new 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery. The main changes made to the new recommendations are reflected. The innovative patient-oriented principle of atrial fibrillation treatment — AF-CARE is considered in detail. An analysis of the updated scale for assessing the risk of stroke and systemic embolism CHA2DS2-VA is given. The article provides definitions of clinical, subclinical, trigger-induced, newly diagnosed, paroxysmal, persistent and permanent forms of atrial fibrillation, algorithms for the treatment of different forms of atrial fibrillation based on the choice of drug therapy taking into account the left ventricular ejection fraction. Much attention is paid to screening and early detection of atrial fibrillation. The categories of patients for whom screening is advisable are determined. The importance of early diagnostics of atrial cardiomyopathy using atrial myocardial strain analysis is emphasized. The role of timely, guideline-based treatment of comorbid pathology such as chronic heart failure, diabetes mellitus, obesity, obstructive sleep apnea, arterial hypertension and others is emphasized in order to prevent atrial fibrillation and, if it occurs, to reduce relapses.Keywords
This publication has 50 references indexed in Scilit:
- Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC‐AF risk scoresAmerican Heart Journal, 2023
- Systemic embolism in amyloid transthyretin cardiomyopathyEuropean Journal of Heart Failure, 2022
- Stroke and Systemic Embolism in Patients with Atrial Fibrillation and Heart Failure According to Heart Failure TypeESC Heart Failure, 2021
- External Validation of the ORBIT Bleeding Score and the HAS-BLED Score in Nonvalvular Atrial Fibrillation Patients Using Direct Oral Anticoagulants (Asian Data from the DIRECT Registry)The American Journal of Cardiology, 2019
- Risk of ischemic stroke and utility of CHA2DS2‐VASc score in women and men with atrial fibrillationClinical Cardiology, 2019
- Comparison of the CHA 2 DS 2 -VASc, CHADS 2 , HAS-BLED, ORBIT, and ATRIA Risk Scores in Predicting Non–Vitamin K Antagonist Oral Anticoagulants-Associated Bleeding in Patients With Atrial FibrillationThe American Journal of Cardiology, 2017
- The HAS‐BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta‐analysisClinical Cardiology, 2015
- Prediction of Thrombo-Embolic Risk in Patients with Hypertrophic Cardiomyopathy (HCM Risk-CVA)European Journal of Heart Failure, 2015
- Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysisJournal of Interventional Cardiac Electrophysiology, 2014
- Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rulesAnnals of Hematology, 2011